JP6279812B2 - アルドステロンシンターゼ阻害薬 - Google Patents

アルドステロンシンターゼ阻害薬 Download PDF

Info

Publication number
JP6279812B2
JP6279812B2 JP2017520427A JP2017520427A JP6279812B2 JP 6279812 B2 JP6279812 B2 JP 6279812B2 JP 2017520427 A JP2017520427 A JP 2017520427A JP 2017520427 A JP2017520427 A JP 2017520427A JP 6279812 B2 JP6279812 B2 JP 6279812B2
Authority
JP
Japan
Prior art keywords
alkyl
mmol
optionally substituted
heterocycle
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017520427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531016A (ja
JP2017531016A5 (enExample
Inventor
キース アール ホーンバーガー
キース アール ホーンバーガー
ケネス マイケル マイヤーズ
ケネス マイケル マイヤーズ
ピーター アレン ネモト
ピーター アレン ネモト
サイモン サプレナント
サイモン サプレナント
フイ ユウ
フイ ユウ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6279812(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2017531016A publication Critical patent/JP2017531016A/ja
Publication of JP2017531016A5 publication Critical patent/JP2017531016A5/ja
Application granted granted Critical
Publication of JP6279812B2 publication Critical patent/JP6279812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017520427A 2014-10-15 2015-10-14 アルドステロンシンターゼ阻害薬 Active JP6279812B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15
US62/064,234 2014-10-15
PCT/US2015/055421 WO2016061161A1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors

Publications (3)

Publication Number Publication Date
JP2017531016A JP2017531016A (ja) 2017-10-19
JP2017531016A5 JP2017531016A5 (enExample) 2017-11-30
JP6279812B2 true JP6279812B2 (ja) 2018-02-14

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520427A Active JP6279812B2 (ja) 2014-10-15 2015-10-14 アルドステロンシンターゼ阻害薬

Country Status (33)

Country Link
US (1) US9745289B2 (enExample)
EP (1) EP3207039B1 (enExample)
JP (1) JP6279812B2 (enExample)
KR (1) KR102441634B1 (enExample)
CN (1) CN107108587B (enExample)
AP (1) AP2017009829A0 (enExample)
AR (1) AR102266A1 (enExample)
AU (1) AU2015333611B2 (enExample)
CA (1) CA2964754C (enExample)
CL (1) CL2017000827A1 (enExample)
CO (1) CO2017003305A2 (enExample)
CY (1) CY1121650T1 (enExample)
DK (1) DK3207039T3 (enExample)
EA (1) EA031766B1 (enExample)
ES (1) ES2724555T3 (enExample)
HR (1) HRP20190896T1 (enExample)
HU (1) HUE043783T2 (enExample)
IL (1) IL251200B (enExample)
LT (1) LT3207039T (enExample)
ME (1) ME03381B (enExample)
MX (1) MX369025B (enExample)
NZ (1) NZ729688A (enExample)
PE (1) PE20170696A1 (enExample)
PH (1) PH12017500595B1 (enExample)
PL (1) PL3207039T3 (enExample)
PT (1) PT3207039T (enExample)
RS (1) RS58651B1 (enExample)
SG (1) SG11201701850UA (enExample)
SI (1) SI3207039T1 (enExample)
TR (1) TR201907755T4 (enExample)
TW (1) TWI731842B (enExample)
UA (1) UA118717C2 (enExample)
WO (1) WO2016061161A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CA3055292A1 (en) * 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN113767095A (zh) 2019-05-01 2021-12-07 勃林格殷格翰国际有限公司 (r)-4-溴苯磺酸(2-甲基环氧乙烷-2-基)甲酯
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
AU2022415313A1 (en) 2021-12-14 2024-05-02 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
CN121181527A (zh) * 2024-06-21 2025-12-23 江苏豪森药业集团有限公司 双稠环类化合物、及其制备方法和应用
WO2026093586A1 (en) 2024-11-04 2026-05-07 AstraZeneca Ireland Limited Combination of a aldosterone synthase inhibitor (asi) and a sodium-glucose co-transporter 2 inhibitor (sglt2i) for use in methods of reducing the risk of cardiovascular and heart failure events in a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073629A1 (es) * 2008-10-07 2010-11-17 Schering Corp Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras
ES2459468T3 (es) * 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
MX350717B (es) * 2011-11-30 2017-09-14 Hoffmann La Roche Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
JP2016516004A (ja) * 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
ES2684050T3 (es) * 2014-07-24 2018-10-01 Boehringer Ingelheim International Gmbh Inhibidores de aldosterona sintasa

Also Published As

Publication number Publication date
EP3207039B1 (en) 2019-03-06
PH12017500595B1 (en) 2020-11-25
WO2016061161A1 (en) 2016-04-21
AP2017009829A0 (en) 2017-03-31
HRP20190896T1 (hr) 2019-07-12
AU2015333611A1 (en) 2017-03-23
CY1121650T1 (el) 2020-07-31
PL3207039T3 (pl) 2019-08-30
AR102266A1 (es) 2017-02-15
CN107108587A (zh) 2017-08-29
NZ729688A (en) 2020-05-29
SG11201701850UA (en) 2017-04-27
TW201629048A (zh) 2016-08-16
TWI731842B (zh) 2021-07-01
CO2017003305A2 (es) 2017-07-19
UA118717C2 (uk) 2019-02-25
RS58651B1 (sr) 2019-05-31
EA201790830A1 (ru) 2017-09-29
SI3207039T1 (sl) 2019-05-31
LT3207039T (lt) 2019-05-10
MX369025B (es) 2019-10-25
KR20170066651A (ko) 2017-06-14
US20160108026A1 (en) 2016-04-21
JP2017531016A (ja) 2017-10-19
ME03381B (me) 2020-01-20
CA2964754A1 (en) 2016-04-21
TR201907755T4 (tr) 2019-06-21
HUE043783T2 (hu) 2019-09-30
MX2017004852A (es) 2017-06-22
PE20170696A1 (es) 2017-06-07
AU2015333611B2 (en) 2020-02-06
CL2017000827A1 (es) 2017-11-03
BR112017005859A2 (pt) 2017-12-26
EP3207039A1 (en) 2017-08-23
PH12017500595A1 (en) 2017-08-30
KR102441634B1 (ko) 2022-09-13
DK3207039T3 (en) 2019-04-23
ES2724555T3 (es) 2019-09-12
IL251200B (en) 2019-05-30
EA031766B1 (ru) 2019-02-28
IL251200A0 (en) 2017-05-29
US9745289B2 (en) 2017-08-29
CA2964754C (en) 2023-01-24
CN107108587B (zh) 2020-05-22
PT3207039T (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
JP2017531016A (ja) アルドステロンシンターゼ阻害薬
JP6067181B2 (ja) アルドステロンシンターゼ阻害薬
AU2012365706B2 (en) Polycyclic derivatives, preparation method and medical uses thereof
KR102378648B1 (ko) 알도스테론 신타아제 억제제
US12612360B2 (en) Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
JP7610985B2 (ja) 心臓サルコメア阻害剤
JP6615896B2 (ja) アルドステロン合成酵素阻害剤
WO2015000412A1 (zh) 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
JP6707084B2 (ja) アルドステロンシンターゼ阻害薬
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
AU2012323038A1 (en) 2-oxo-piperidinyl derivatives
BR112017005859B1 (pt) Inibidores de aldosterona sintase, seus usos e sais farmaceuticamente aceitáveis e composição farmacêutica
HK1243068B (en) Aldosterone synthase inhibitors
HK1243068A1 (en) Aldosterone synthase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180117

R150 Certificate of patent or registration of utility model

Ref document number: 6279812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250